Get the Stockscreener App
1.549
4.66%
0.069
Cel-Sci Corp. stock is traded at $1.549, with a volume of 126.69K.
It is up +4.66% in the last 24 hours and down -8.34% over the past month.
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
See More
Previous Close:
$1.48
Open:
$1.5
24h Volume:
126.69K
Relative Volume:
0.40
Market Cap:
$22.45M
Revenue:
-
Net Income/Loss:
$-23.81M
P/E Ratio:
-0.5367
EPS:
-2.8859
Net Cash Flow:
$-17.01M
1W Performance:
+4.66%
1M Performance:
-8.34%
6M Performance:
-75.37%
1Y Performance:
-35.73%
1-Day Range:
$1.4621
$1.5603
1-Week Range:
$1.43
$1.59
52-Week Range:
$0.89
$13.48
Cel-Sci Corp. Stock (CVM) Company Profile
Name
Cel-Sci Corp.
Sector
Industry
Phone
703-506-9460
Address
8229 Boone Boulevard, Suite 802, Vienna, VA
Compare CVM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVM
Cel-Sci Corp.
|
1.549 | 21.45M | 0 | -23.81M | -17.01M | -2.8859 |
VRTX
Vertex Pharmaceuticals Inc
|
444.62 | 108.72B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
625.59 | 64.89B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.17 | 50.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.68 | 39.06B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.32 | 33.16B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-02-15 | Initiated | Dawson James | Buy |
Cel-Sci Corp. Stock (CVM) Latest News
CVM - Finviz
[RW] CEL SCI CORP SEC Filing - Stock Titan
CVM: CEL-SCI Advances Multikine Toward Regulatory Approval - GuruFocus
Cel Sci CEO Geert Kersten’s trust buys $360,000 in common stock By Investing.com - Investing.com South Africa
Cel Sci CEO Geert Kersten’s trust buys $360,000 in common stock - Investing.com Australia
Cel Sci Insider Bought Shares Worth $360,000, According to a Recent SEC Filing - marketscreener.com
CEL-SCI (NYSE: CVM) trust buys 300K restricted shares at $1.20 - Stock Titan
CEL-SCI adds Saudi partner, U.S. trial for head and neck cancer drug - Stock Titan
Insider Stock Purchases: May 18, 2026 - Moomoo
Cel-Sci: Fiscal Q2 Earnings Snapshot - cbs19news.com
CEL SCI CORP 1H 2026: Net loss $(10.94M), Diluted EPS $(1.35) — 10-Q Summary - TradingView
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 - marketscreener.com
CEL-SCI (NYSE: CVM) reports $10.9M loss and just $1.9M in cash - Stock Titan
CEL-SCI Partners with Amarox for Multikine Cancer Immunotherapy Commercialization in Saudi Arabia and GCC Region 12 - Minichart
CVM SEC FilingsCEL-SCI Corp 10-K, 10-Q, 8-K Forms - Stock Titan
CEL-SCI (NYSE: CVM) partners with Amarox on Multikine in Saudi Arabia - Stock Titan
CEO Geert Kersten Increases Stake in CEL-SCI Corp with Recent Sh - GuruFocus
Cel-Sci Corporation Common Stock (NY: CVM - FinancialContent
CEO Geert Kersten Increases Stake in CEL-SCI Corp with Recent Share Purchase - GuruFocus
Cel Sci CEO Geert Kersten acquires $119,000 in common stock - Investing.com India
Cel Sci CEO Geert Kersten acquires $119,000 in common stock By Investing.com - Investing.com South Africa
CEL SCI (CVM) CEO Geert Kersten purchases 100,000 restricted shares - Stock Titan
CEL-SCI Raises $7.2 Million in Stock Offering; Placement Agreement With ThinkEquity - TradingView
CEL-SCI (NYSE: CVM) prices $7.2M best-efforts stock offering - Stock Titan
CEL-SCI closes $7.2M public offering at $1.20 per share - Investing.com
Cancer immunotherapy firm CEL-SCI raises $7.2M for Multikine - Stock Titan
CEL‑SCI (NYSE American: CVM) to sell 6.0M shares; raises ~$6.5M net - Stock Titan
Cel-Sci Corp files for offering of 6 million shares of common stockSEC filing - marketscreener.com
Cel-Sci Corp Files For Offering Of 6 Million Shares Of Common Stock- SEC Filing - TradingView
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Get insights into the top gainers and losers of Tuesday's pre-market session. - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
[EFFECT] CEL SCI CORP SEC Filing - Stock Titan
Why Harmonic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Did CEL-SCI Stock Plunge After Its Latest Offering - Kavout
CVM: ThinkEquity Completes Sole Management of Offering - GuruFocus
CEL-SCI prices $7.2M public offering at $1.20 per share By Investing.com - Investing.com South Africa
CEL-SCI prices $7.2M public offering at $1.20 per share - Investing.com
Cancer immunotherapy firm CEL-SCI seeks $7.2M to develop Multikine - Stock Titan
CEL-SCI Corporation Announces Pricing of Public Offering - Yahoo Finance
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
Strategic Partnership for CEL-SCI (CVM) Enhances Multikine's Mar - GuruFocus
CEL-SCI partners with Amarox for Multikine in Saudi Arabia By Investing.com - Investing.com South Africa
CEL-SCI partners with Amarox for Multikine in Saudi Arabia - Investing.com India
Saudi bid to fast-track cancer immunotherapy with new CEL-SCI deal - Stock Titan
Cel-Sci CVM shares surge 10% after Q4 earnings beat; quarterly loss narrower than analysts expected.Balance Sheet - newser.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
EDGAR Filing Documents for 0001654954-26-004295 - SEC.gov
CEL-SCI (NYSE: CVM) moves to fund Multikine with $13.7M best efforts stock sale - Stock Titan
New LowStock ScreenerSnapshot - Finviz
Cel-Sci Corp. Stock (CVM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):